REFERENCES
1. Dehner LP. The evolution of the diagnosis and understanding of primitive and embryonic neoplasms in children: living through an epoch. Mod Pathol. 1998 Jul;11(7):669-85.
2. Chiang S, Snuderl M, Kojiro-Sanada S, et al. Primitive Neuroectodermal Tumors of the Female Genital Tract: A Morphologic, Immunohistochemical, and Molecular Study of 19 Cases. Am J Surg Pathol. Jun 2017;41(6):761-772.
3. Chao X, Bi Y, Li L. Ovarian primary primitive neuroectodermal tumor: a review of cases at PUMCH and in the published literature. Orphanet J Rare Dis. Jun 19 2019;14(1):147.
4. Ulbright TM, Hattab EM, Zhang S, et al. Primitive neuroectodermal tumors in patients with testicular germ cell tumors usually resemble pediatric-type central nervous system embryonal neoplasms and lack chromosome 22 rearrangements. Mod Pathol 23, 972–980 (2010)
5. Delattre O, Zucman J, Melot T, et al. The Ewing family of tumors–a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med. Aug 4 1994;331(5):294-9.
6. Al-Hader AA, Jain A, Al-Nasrallah N, Einhorn LH. Metastatic malignant transformation of teratoma to primitive neuroectodermal tumor (PNET): results with PNET-based chemotherapy. Am J Clin Oncol. 2015 Aug;38(4):364-6.
7. Shen L, Qiang T, Li Z, Ding D, Yu Y, Lu S. First-line crizotinib versus platinum-pemetrexed chemotherapy in patients with advanced ROS1-rearranged non-small-cell lung cancer. Cancer Med. May 2020;9(10):3310-3318. doi:10.1002/cam4.2972
8. Schöffski P, Kubickova M, Wozniak A, et al. Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE. Eur J Cancer. 2021 Oct;156:12-23.
9. Foster JH, Voss SD, Hall DC, et al. Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children’s Oncology Group Study (ADVL0912). Clin Cancer Res. 2021 Jul 1;27(13):3543-3548.
10. Ngo C, Grinda T, Bolieve A, et al. Durable response to crizotinib in metastatic angiomatoid fibrous histiocytoma with EWSR1-CREB1 fusion and ALK overexpression. Ann Oncol. 2022 May 12;S0923-7534(22)01164-4.
11. Hasan MK, Nafady A, Takatori A, et al. ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma. Sci Rep. 2013 Dec 20;3:3450.
12. Kramer M, Ribeiro D, Arsenian-Henriksson M, Deller T, Rohrer H. Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling. J Neurosci. Oct 5 2016;36(40):10425-10439. doi:10.1523/JNEUROSCI.0183-16.2016
13. Moreno MM, Barrell WB, Godwin A, Guille M, Liu KJ. Anaplastic lymphoma kinase 1, a neuroblastoma associated gene, is expressed in neural crest domains during embryonic development of Xenopus. Gene Expr Patterns. Jun 2021;40:119183.
14. Montavon G, Jauquier N, Coulon A, et al. Wild-type ALK and activating ALK-R1275Q and ALK-F1174L mutations upregulate Myc and initiate tumor formation in murine neural crest progenitor cells. Oncotarget. Jun 30 2014;5(12):4452-66.
15. Debruyne DN, Bhatnagar N, Sharma B, et al. ALK inhibitor resistance in ALK(F1174L)-driven neuroblastoma is associated with AXL activation and induction of EMT. Oncogene. 2016 Jul 14;35(28):3681-91.
16. Mazot P, Cazes A, Dingli F, et al. Internalization and down-regulation of the ALK receptor in neuroblastoma cell lines upon monoclonal antibodies treatment. PLoS One. 2012;72:e33581.
17. Umapathy G, Mendoza-Garcia P, Hallberg B, Palmer RH. Targeting anaplastic lymphoma kinase in neuroblastoma. APMIS. May 2019;127(5):288-302.
18. Zafar A, Wang W, Liu G, et al. Molecular targeting therapies for neuroblastoma: Progress and challenges. Med Res Rev. Mar 2021;41(2):961-1021.
19. Vasseur A, Cabel L, Geiss R, et al. Efficacy of Lorlatinib in Primary Crizotinib-Resistant Adult Neuroblastoma Harboring ALK Y1278S Mutation. JCO Precis Oncol. 2019 Dec;3:1-5.
20. Braun TP, Eide CA, Druker BJ, et al. Response and Resistance to BCR-ABL1-Targeted Therapies. Cancer Cell. 2020 Apr 13;37(4):530-542.